PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 28834474
OWN - NLM
STAT- MEDLINE
DA  - 20170823
DCOM- 20170825
LR  - 20170828
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 377
IP  - 8
DP  - 2017 Aug 24
TI  - Adjuvant Capecitabine for Breast Cancer.
PG  - 791-2
LID - 10.1056/NEJMc1708487 [doi]
FAU - Toi, Masakazu
AU  - Toi M
AD  - Kyoto University, Kyoto, Japan [email protected]
FAU - Masuda, Norikazu
AU  - Masuda N
AD  - National Hospital Organization Osaka National Hospital, Osaka, Japan
FAU - Ohashi, Yasuo
AU  - Ohashi Y
AD  - Chuo University, Tokyo, Japan
LA  - eng
PT  - Letter
PT  - Comment
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 6804DJ8Z9U (Capecitabine)
RN  - U3P01618RT (Fluorouracil)
SB  - AIM
SB  - IM
CON - N Engl J Med. ;377(8):790-1. PMID: 28836422
CON - N Engl J Med. 2017 Aug 24;377(8):791. PMID: 28834475
MH  - Antimetabolites, Antineoplastic
MH  - Antineoplastic Combined Chemotherapy Protocols
MH  - *Breast Neoplasms
MH  - *Capecitabine
MH  - Chemotherapy, Adjuvant
MH  - Deoxycytidine
MH  - Fluorouracil
MH  - Humans
MH  - Treatment Outcome
EDAT- 2017/08/24 06:00
MHDA- 2017/08/26 06:00
CRDT- 2017/08/24 06:00
AID - 10.1056/NEJMc1708487 [doi]
AID - 10.1056/NEJMc1708487#SA3 [pii]
PST - ppublish
SO  - N Engl J Med. 2017 Aug 24;377(8):791-2. doi: 10.1056/NEJMc1708487.